Form 4/A for AKBA Akebia Therapeutics, Inc.
Accepted 2022-02-18 00:00:00 ET · period of report 2018-12-12 · accession 0001562180-22-001654 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2022-02-18 | 2018-12-12 | AKBA | Butler John P. | CEO, Pres, Dir | J - Other | — | +1,248 | 375.9K | +0.3% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2018-12-12 | J | A | 1,248 | — | 375,865 | D | — | — | (F1) Pursuant to the Agreement and Plan of Merger, dated as of June 28, 2018 (as amended, the "Merger Agreement"), each share of common stock of Keryx Biopharmaceuticals, Inc. owned by the Reporting Person at the effective time of the transactions contemplated by the Merger Agreement was automatically converted into 0.37433 shares of the Issuer's common stock. (F2) The market value of each share of the Issuer's common stock received pursuant to the Merger Agreement is $8.94, based on the closing trading price of Akebia common stock on December 12, 2018. |